Spruce Biosciences
(NASDAQ) SPRB
Spruce Biosciences Financials at a Glance
Market Cap
$144.62M
Revenue (TTM)
$0.00
Net Income (TTM)
-$37.19M
EPS (TTM)
-$37.70
P/E Ratio
-1.39
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Price
$51.61
Volume
68,772
Open
$52.81
Price
$51.61
Volume
68,772
Open
$52.81
Previous Close
$52.51
Daily Range
$51.03 - $55.21
52-Week Range
$4.96 - $240.00
Estimated Earnings Date
Aug 13, 2026
Dividend
$0.00
Beta (Volatility)
1.32 (Average)
Price
$51.61
Volume
68,772
Open
$52.81
Previous Close
$52.51
Daily Range
$51.03 - $55.21
52-Week Range
$4.96 - $240.00
Estimated Earnings Date
Aug 13, 2026
SPRB News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Spruce Biosciences
Industry
Biotechnology
Sector
Health CareEmployees
14
CEO
Javier Szwarcberg, MD
Website
sprucebio.comHeadquarters
Daly City, CA 94014, US
SPRB Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-155.40%
Return on Capital
-84.42%
Return on Assets
-66.22%
Earnings Yield
-71.94%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$144.62M
Shares Outstanding
2.75M
Volume
68.77K
Avg. Volume
76.70K
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$34.01M
EBITDA
-$36.20M
Operating Cash Flow
-$29.33M
Capital Expenditure
-$10.00K
Free Cash Flow
-$29.34M
Cash & ST Invst.
$54.08M
Total Debt
$7.12M
Spruce Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$144.62M
N/A
Market Cap/Employee
$7.23M
N/A
Employees
20
N/A
Net Income
-$12.27M
+12.6%
EBITDA
-$11.34M
+19.0%
Quarterly Fundamentals
Total Cash
$54.08M
+111.1%
Total Debt
$7.12M
+210.3%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$5.80M
+779.5%
Short Term Debt
$1.33M
-18.9%
Return on Assets
-66.22%
N/A
Return on Invested Capital
-76.63%
N/A
Free Cash Flow
-$8.74M
+31.3%
Operating Cash Flow
-$8.73M
+31.4%